BioCentury | Jul 15, 2013
Company News

Valeant Pharmaceuticals, Zogenix sales and marketing update

...the deal was terminated shortly afterwards. Valeant gained the product in its 2005 acquisition of Xcel Pharmaceuticals Inc....
BioCentury | Jun 20, 2011
Clinical News

Potiga ezogabine regulatory update

...payment to Meda from Valeant, which gained the compound through its 2005 acquisition of Xcel Pharmaceuticals Inc. Xcel...
...payment to Meda from Valeant, which gained the compound through its 2005 acquisition of Xcel Pharmaceuticals Inc. Xcel...
BioCentury | Jun 14, 2010
Company News

Almac sales and marketing update

...Almac launched its XCEL array biomarker discovery technology to identify biomarkers in multiple disease areas. The...
BioCentury | Jan 4, 2010
Clinical News

Retigabine regulatory update

...through its acquisition of Viatris GmbH & Co. Viatris granted rights to the compound to Xcel Pharmaceuticals Inc....
BioCentury | Dec 31, 2009
Company News

FDA accepts retigabine NDA

...through its acquisition of Viatris GmbH & Co. Viatris granted rights to the compound to Xcel Pharmaceuticals Inc....
BioCentury | Nov 9, 2009
Clinical News

Retigabine regulatory update

...potassium channel opener and potentiator of GABA. Valeant gained retigabine through its 2005 acquisition of Xcel Pharmaceuticals Inc....
BioCentury | Sep 1, 2008
Company News

Valeant, GlaxoSmithKline, Meda deal

...will fund development of the other compounds. Valeant gained retigabine through its 2005 acquisition of Xcel Pharmaceuticals Inc....
BioCentury | Aug 29, 2008
Top Story

Valeant, GSK in retigabine deal

...GSK funding development of the other compounds. Valeant gained retigabine through its 2005 acquisition of Xcel...
BioCentury | May 19, 2008
Clinical News

Retigabine: Phase III data

...for placebo. RESTORE2 has an SPA from FDA. Valeant gained retigabine through its acquisition of Xcel Pharmaceuticals Inc....
BioCentury | Feb 18, 2008
Finance

Ebb & Flow

...in patients with epilepsy. The company, which acquired the compound through its 2005 acquisition of Xcel...
Items per page:
1 - 10 of 89
BioCentury | Jul 15, 2013
Company News

Valeant Pharmaceuticals, Zogenix sales and marketing update

...the deal was terminated shortly afterwards. Valeant gained the product in its 2005 acquisition of Xcel Pharmaceuticals Inc....
BioCentury | Jun 20, 2011
Clinical News

Potiga ezogabine regulatory update

...payment to Meda from Valeant, which gained the compound through its 2005 acquisition of Xcel Pharmaceuticals Inc. Xcel...
...payment to Meda from Valeant, which gained the compound through its 2005 acquisition of Xcel Pharmaceuticals Inc. Xcel...
BioCentury | Jun 14, 2010
Company News

Almac sales and marketing update

...Almac launched its XCEL array biomarker discovery technology to identify biomarkers in multiple disease areas. The...
BioCentury | Jan 4, 2010
Clinical News

Retigabine regulatory update

...through its acquisition of Viatris GmbH & Co. Viatris granted rights to the compound to Xcel Pharmaceuticals Inc....
BioCentury | Dec 31, 2009
Company News

FDA accepts retigabine NDA

...through its acquisition of Viatris GmbH & Co. Viatris granted rights to the compound to Xcel Pharmaceuticals Inc....
BioCentury | Nov 9, 2009
Clinical News

Retigabine regulatory update

...potassium channel opener and potentiator of GABA. Valeant gained retigabine through its 2005 acquisition of Xcel Pharmaceuticals Inc....
BioCentury | Sep 1, 2008
Company News

Valeant, GlaxoSmithKline, Meda deal

...will fund development of the other compounds. Valeant gained retigabine through its 2005 acquisition of Xcel Pharmaceuticals Inc....
BioCentury | Aug 29, 2008
Top Story

Valeant, GSK in retigabine deal

...GSK funding development of the other compounds. Valeant gained retigabine through its 2005 acquisition of Xcel...
BioCentury | May 19, 2008
Clinical News

Retigabine: Phase III data

...for placebo. RESTORE2 has an SPA from FDA. Valeant gained retigabine through its acquisition of Xcel Pharmaceuticals Inc....
BioCentury | Feb 18, 2008
Finance

Ebb & Flow

...in patients with epilepsy. The company, which acquired the compound through its 2005 acquisition of Xcel...
Items per page:
1 - 10 of 89